MD1340Z - Method for predicting the risk of cardiorenal syndrome in heart failure with intermediate and reduced ejection fraction - Google Patents
Method for predicting the risk of cardiorenal syndrome in heart failure with intermediate and reduced ejection fraction Download PDFInfo
- Publication number
- MD1340Z MD1340Z MDS20180117A MDS20180117A MD1340Z MD 1340 Z MD1340 Z MD 1340Z MD S20180117 A MDS20180117 A MD S20180117A MD S20180117 A MDS20180117 A MD S20180117A MD 1340 Z MD1340 Z MD 1340Z
- Authority
- MD
- Moldova
- Prior art keywords
- cardiorenal syndrome
- risk
- heart failure
- predicting
- ejection fraction
- Prior art date
Links
- 208000004990 Cardiorenal syndrome Diseases 0.000 title abstract 3
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 150000003626 triacylglycerols Chemical class 0.000 abstract 3
- 238000003745 diagnosis Methods 0.000 abstract 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 abstract 1
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 abstract 1
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 210000004898 n-terminal fragment Anatomy 0.000 abstract 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 230000033764 rhythmic process Effects 0.000 abstract 1
- 230000003488 thyrotrophic effect Effects 0.000 abstract 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention relates to medicine, in particular to cardiology and nephrology.Summary of the invention consists in that it is determined the patient's age (V), the duration of cardiovascular disease (DBCV) and the presence of rhythm disturbances in the anamnesis (TR), is conducted the clinical and paraclinical examination with the determination of the severity of heart failure (IC) and the presence of ischemic cardiopathy (CPI), the level of N-terminal fragment of brain natriuretic peptide (NTproBNP) precursor, the serum level of triglycerides (TRIG) and serum thyrotrophic hormone (TSH), and the discriminant function (F) is calculated by the formula:F = - 16,775 + 0.111 · V + 0.145 · NTproBNP + 2.205 · TRIG + 1.413 · IC + 1.693 · TR + 0.499 · CPI + 0.040 · DBCV + 0.082 · TSH,in the case when F > 0 is confirmed the diagnosis or predicted an increased risk of cardiorenal syndrome, and F < 0 - is excluded the diagnosis or predicted a low risk of cardiorenal syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20180117A MD1340Z (en) | 2018-12-06 | 2018-12-06 | Method for predicting the risk of cardiorenal syndrome in heart failure with intermediate and reduced ejection fraction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20180117A MD1340Z (en) | 2018-12-06 | 2018-12-06 | Method for predicting the risk of cardiorenal syndrome in heart failure with intermediate and reduced ejection fraction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD1340Y MD1340Y (en) | 2019-06-30 |
| MD1340Z true MD1340Z (en) | 2020-01-31 |
Family
ID=67069690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20180117A MD1340Z (en) | 2018-12-06 | 2018-12-06 | Method for predicting the risk of cardiorenal syndrome in heart failure with intermediate and reduced ejection fraction |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD1340Z (en) |
-
2018
- 2018-12-06 MD MDS20180117A patent/MD1340Z/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD1340Y (en) | 2019-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yee et al. | Cerebral salt wasting: pathophysiology, diagnosis, and treatment | |
| Mattioli et al. | Cardiovascular prevention in women: a narrative review from the Italian Society of Cardiology working groups on ‘Cardiovascular Prevention, Hypertension and peripheral circulation’and on ‘Women Disease’ | |
| Madamanchi et al. | Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure | |
| Tibrewala et al. | Heart failure with preserved ejection fraction in women | |
| Clifton | Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? | |
| Aimo et al. | Effect of sex on reverse remodeling in chronic systolic heart failure | |
| Yasar et al. | Is non-thyroidal illness syndrome a predictor for prolonged weaning in intubated chronic obstructive pulmonary disease patients? | |
| RU2016112154A (en) | METHOD FOR FORECASTING RISK OF SEVERE UNWANTED HEART PHENOMENON | |
| Potpara et al. | External validation of the simple NULL-PLEASE clinical score in predicting outcome of out-of-hospital cardiac arrest | |
| Sachdev et al. | Takotsubo cardiomyopathy | |
| Daugherty et al. | Cardiovascular disease in women across the lifespan: the importance of sleep | |
| Mazzone et al. | Development and validation of a risk stratification score for new‐onset atrial fibrillation in STEMI patients undergoing primary percutaneous coronary intervention | |
| Lee et al. | The impact of subclinical hypothyroidism or thyroid autoimmunity on coronary vasospasm in patients without associated cardiovascular risk factors | |
| Peacock | Using the emergency department clinical decision unit for acute decompensated heart failure | |
| Okabe et al. | Relationship between worsening renal function and long-term cardiovascular mortality in heart failure patients | |
| MD1340Z (en) | Method for predicting the risk of cardiorenal syndrome in heart failure with intermediate and reduced ejection fraction | |
| Yamagishi et al. | Comparison of risk factors for acute worsening renal function in heart failure patients with and without preserved ejection fraction | |
| Vu et al. | A case of Kounis syndrome presenting as coronary artery spasm associated with acetaminophen infusion | |
| Lim et al. | Exercise capacity and brain natruiretic peptide in hypertension | |
| Shimizu et al. | A case demonstrating the cardio-vascular interaction by a new cardio-ankle vascular index during the treatment of concentric hypertrophy | |
| Januzzi | Use of biomarkers to “guide” care in chronic heart failure: what have we learned (so far)? | |
| Alfraji et al. | Nonischemic dilated cardiomyopathy in untreated long-term psoriatic arthritis: a newly recognized association: a case report with mini review | |
| Solomon et al. | Rapid progression of aortic stenosis after initiation of teriparatide treatment: a case report | |
| Vaduganathan et al. | A roadmap to inpatient heart failure management | |
| Ahmad et al. | Polyglandular endocrine emergency: lessons from a patient, which a book cannot teach |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) |